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INTRODUCTION
Gender differences in the development of cardiovascular
diseases have been documented in both human and animal
studies. The rate of incidence of cardiovascular disease is lower
in premenopausal women than in men, but increases sharply
in postmenopausal women (1). Among the clinical conse-
quences of postmenopausal estrogen deficiency, the deaths
associated with cardiovascular diseases represent the largest
concern in public health. Many studies have demonstrated
that estrogen replacement therapy reduces the risk of cardio-
vascular disease in postmenopausal women (2). Animal stud-
ies also demonstrate gender differences in the development
of cardiovascular diseases (3-5). Thus, circulating endogenous
estrogen is proposed to protect against cardiovascular disease.
However, mechanisms by which estrogen induces its protec-
tive effects are not fully understood.
Various vasoactive substances and growth factors have been
implicated in cardiac and vascular remodeling, as well as fur-
ther degenerative transformation of these tissues (6). A criti-
cal role of the cardiac renin-angiotensin system (RAS), among
others, has been recognized (7, 8). Increased activity of the
cardiac RAS has been confirmed both in humans (9) and ani-
mal models of cardiac failure (10, 11), whereas inhibition of
the RAS decreased ventricular remodeling and improved car-
diac function (12, 13).
Cardiac hypertrophy is known to be one of the most critical
risk factors of heart diseases. It has been demonstrated that
monocrotaline (MCT) treatment produces pulmonary hyper-
tension and right ventricular (RV) hypertrophy in male rats
but not in female rats (4, 14). We previously found enhanced
gene expressions of the cardiac RAS in the hypertrophied RV
of male rats (15). The present study evaluated 1) the impor-
tance of the ovairan function and the RAS in the progression
of the pulmonary hypertension, and 2) RV hypertrophy in
MCT treated rats. We examined the cardiac expression of
genes that contribute to the pathogenesis of cardiac hypertro-
phy, such as the RAS components, TGF- 1, and endothelin-
1 as well as histological changes in the lung and heart. Al-
though this MCT rat model has no human equivalent, as a
study design, we used a system of MCT-induced cardiopul-
monary dysfunction to investigate possible beneficial effects
of estrogen and inhibition of angiotensin converting enzyme.
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Estrogen and Enalapril attenuate the Development of Right Ventricular
Hypertrophy induced by Monocrotaline in Ovariectomized Rats
The present study evaluated the importance of ovarian functions and the renin-
angiotensin system in the progression of the right ventricular (RV) hypertrophy. Female
Sprague-Dawley rats were bilaterally ovariectomized (Ovx) and injected with monocro-
taline (MCT, 60 mg/kg, sc). Four weeks after MCT-treatment, only the male and Ovx
female rats showed marked RV hypertrophy. The hypertrophied RV of the male-MCT
and Ovx-MCT rats exhibited remarkably elevated renin mRNA levels. Gene expres-
sion levels of angiotensinogen, TGF- 1, and endothelin-1 in the hypertrophied RV
also increased, but to the less degree than did the renin mRNA. To investigate ben-
eficial effects of estrogen or enalapril on progression of the pulmonary hypertension
and RV hypertrophy, histological changes of the lung and heart were examined. Sham-
MCT female rats showed histological changes indicating pulmonary hypertension
without RV hypertrophy. In contrast, Ovx-MCT rats showed marked RV hypertrophy
with pathological changes, denoting severe pulmonary and myocardial injuries. Estro-
gen- or enalapril-treated Ovx-MCT rats did not show RV hypertrophy, and showed
remarkably ameliorated ultrastructural changes in the lung and RV. These results
from this rat model suggest that both estrogen and inhibition of the renin-angiotensin
system have protective functions against the development of the pulmonary hyper-
tension and cardiac remodeling.
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MATERIALS AND METHODS
Ovariectomy and Development of RV Hypertrophy
Thirteen-week-old male and female Sprague-Dawley rats
were used. Female rats were randomly divided, and a bilater-
al ovariectomy or sham operation was performed using pen-
tobarbital anesthesia (40 mg/kg, intraperitoneal, ip). After
two weeks, the ovariectomized (Ovx) and the sham-operated
female rats, as well as the intact male rats, were given a single
subcutaneous injection of 60 mg MCT/kg (Sigma, St. Louis,
MO, U.S.A.). MCT was dissolved in phosphate-buffered saline
(PBS) and the pH adjusted to 7.4 with 0.5 N HCl. The con-
trol rats were injected with saline.
Four weeks after the MCT treatment, all the rats were anes-
thetized with ether, and the heart and lungs were removed from
each rat. The heart was divided into the RV and left ventricle
plus septum (LV+S), and each portion was separately weighed.
RV samples were rapidly frozen in liquid nitrogen and then
stored at -80℃ until total RNA isolation. The experiment
was carried out following the guidelines for animal care pro-
vided by Kyungpook National University in Korea.
RNA Extraction and RT-PCR
Total RNA was extracted according to the method of Chom-
czynski and Sacchi (16) with slight modifications as described
previously (17). Samples of RNA were stored at -80℃ as a
suspension in 70% ethanol. RNA was spectrophotometrical-
ly quantified by measuring the optical density of samples at
260/280 nm.
The nucleotide sequence of the primers were used as pre-
viously indicated (15). Total RNA (20  g) was primed with
oligo (dT) primers, and the first strand cDNA was synthesized
using Moloney murine leukemia virus reverse transcriptase
(Promega, Madison, WI, U.S.A.) in a 50  L of reaction vol-
ume for 90 min at 37℃. PCR cycles were performed in a DNA
thermal cycler (PTC-100, M.J Research, Watertown, MA,
U.S.A.) with the following profile: denaturation for 45 sec at
94℃, annealing for 45 sec at 56℃for GAPDH, renin, AT1A,
AT1B and TGF- 1 primers and 1 min extension step at 72
℃; denaturation for 45 sec at 94℃, annealing for 45 sec at
58℃ for angiotensinogen primers and 1 min extension step
at 72℃; denaturation for 45 sec at 94℃, annealing for 45
sec at 56℃ for ET-1 primers and for 90 sec extension step at
72℃. After the end of the PCR, one-tenth reaction mixture
was separated on a 1% agarose gel, containing 0.5  g/mL of
ethidium bromide.
Densitometric Analysis
Polaroid film was scanned using an Epson (GT-9500) scan-
ner with a resolution of 72 DPI. The resulting image was ana-
lyzed using the NIH-Image analysis program (NIH, Bethe-
da, MD, U.S.A.). The scale of each band was expressed by
multiplying the values of mean density and total area of the
band. The resulting scale was used to quantify each band.
Histological Evaluation
Eighteen female rats (13 week old) were randomly divided
into six groups, and were either sham-operated or ovariec-
tomized. Two weeks after the operation, MCT (60 mg/kg,
subcutaneous, s.c.) or vehicle was given to the Ovx and sham-
operated rats, and 17 -estradiol (50  g s.c., twice/week) or
enalapril (250 mg/L drinking water) was treated in Ovx-MCT
rats for 4 weeks. Then the heart and lungs were removed and
weighed, and small blocks of the lung and RV were fixed for
morphological examination.
RV walls were fixed by immersion in cold 2.5% glutaralde-
hyde solution (pH 7.4). After fixation, samples were rinsed
and postfixed with 1% osmium tetroxide in 0.1 M PBS for
2 hr at room temprature, dehydrated through a graded series
of ethanol to propylene oxide and embedded in epoxy resin.
Block sections, 60-70 nm thick, were cut, and then stained
with uranyl acetate and lead citrate.
Lung tissues were cut into small sizes and fixed by 10% neu-
tral buffered formalin. Then air was removed from the tissue
by capping the sample vial and by applying a small vacuum
with a 50 mL syringe. After fixation, samples were washed in
running tap water, dehydrated through a graded series of
ethanol to xylene, and embedded in paraffin. Paraffin block
sections, 4  m thick, were cut and then stained with hema-
toxylin and eosin.
Statistical Analysis
Data are expressed as mean±SE. The data were analyzed
statistically using the SPSS for Windows statistical program.
Comparisons between the control and MCT-treated male
rats were made with an unpaired Student’ s t-test. One-way
ANOVA with Tukey’ s multiple test was used to compare the
four female groups. Differences were considered statistically
significant at a value of p<0.05.
RESULTS
Effect of Ovariectomy on the Development of RV
Hypertrophy and Gene Expressions of the Cardiac
RAS, TGF- 1 and Endothelin-1
The results of the body, heart, and lung weights are shown
in Table 1. The body weight (BW) of the Ovx rats was signif-
icantly greater than that of the sham-operated rats through-
out the experimental period. Treatment with MCT at a dose of
60 mg/kg caused significantly lower body weights in both
the male and the Ovx female groups, compared with theirEffects of Estrogen and Enalapril on Cardiac Remodeling 643
respective control groups. The lung and RV weights were simi-
lar between the sham and the Ovx female groups. However,
the MCT-treated males and the Ovx females showed signif-
icantly higher weight ratios of lung/BW, RV/BW and RV/
(LV+S) than did their respective controls. The weight ratio
of (LV+S)/BW in the MCT-treated males and the Ovx females
was not different from their respective controls. Interesting-
ly, the sham-MCT females showed a significantly increased
lung weight without significant RV hypertrophy.
Changes in gene expressions of the cardiac RAS components,
TGF- 1, and endothelin-1 are shown in Table 2. Renin mRNA
level both in RV and LV was very low in a basal state (Fig. 1),
but ovariectomy increased RV renin mRNA level 3.8-fold. The
Ovx-MCT group showed 9.4-fold higher RV renin mRNA
level than the Ovx-control group. The male- and sham-MCT
groups showed approximately 6~8-fold higher RV renin
mRNA levels than their respective control groups. LV renin
mRNA expression in the MCT-treated male and Ovx rats also
increased approximately 2-fold, but the increase was marked-
ly lower than the RV level (data not shown). Neither the Ovx-
control nor the sham-MCT group showed alteration in LV
renin mRNA expression.
RV angiotensinogen mRNA expression increased two-fold
in the male-MCT group, but was not significantly increased
in MCT treated female groups. LV angiotensinogen mRNA
expression was not significantly changed either in the MCT
treated male, sham or Ovx female groups (data not shown).
Gene expression of Ang II-AT1A and AT1B receptors in RV in-
creased slightly but significantly only in the Ovx-MCT group.
Four-week treatment of MCT elevated RV TGF- 1 mRNA
expression 3-fold in male rats, but lesser degree in the sham
and the Ovx groups. MCT-treatment slightly elevated TGF- 1
mRNA expression in LV to the lesser degree than that in the
RV of the male and the Ovx rats (data not shown). The Ovx-
control rats did not show significant increase in TGF- 1mRNA
level either in RV or LV. Endothelin-1 mRNA levels increased
significantly in the RV of male- and Ovx-MCT rats, but not
in the Ovx or sham-MCT rats.
Male Female
Control MCT Sham Ovx-control Sham-MCT Ovx-MCT
Initial BW, g 298±7.5 295±7.6* 225±9.6 232±5.8 236±6.8 232±8.6
Final BW, g 410±14.6 354±8.7* 292±18
bc 355±14.1
a 280±4.5
c 314±13.6
b
RV/BW, ×10
-4 6.8±0.2 13.5±1.6* 5.9±0.4
bc 5.5±0.2
c 7.0±0.7
b 15.1±1.1
a
(LV+S)/BW, ×10
-4 20.5±1.1 20.6±0.3 22.0±1.2 20.0±0.7 22.1±0.5 22.5±0.9
RV/(LV+S) 0.33±0.01 0.65±0.07* 0.27±0.01
b 0.28±0.01
b 0.32±0.04
b 0.67±0.04
a
Lung/BW, ×10
-3 4.1±0.34 6.6±0.37* 4.6±0.24
b 4.0±0.18
b 6.9±0.60
a 7.5±0.72
a
Values are mean±SE of six rats in each group. *p<0.01, vs. control in male rats by t-test. Different superscript letters in female rats show significant
differences at p<0.05 by Tukey’ s test. RV, right ventricle; LV, left ventricle; S, septum.
Table 1. Body weight (BW), the wet weights of hearts and lungs of the control and monocrotaline (MCT)-injected male rats, as well as
the ovariectomized (Ovx) and the sham-operated female rats
Male Female
Control MCT Sham Ovx-control Sham-MCT Ovx-MCT
Renin 1 6.1±0.07** 1
C 3.8±0.02
C 7.8±0.03
b 35.9±0.12
a
Aogen 1 2.0±0.12* 1 1.2±0.11 0.9±0.07 1.3±0.03
AT1A 1 1.4±0.09 1
b 1.0±0.10
b 0.9±0.15
ab 1.4±0.02
a
AT1B 1 1.0±0.01 1
b 0.6±0.07
b 0.6±0.07
b 1.5±0.03
a
TGF- 1 1 3.1±0.04** 1
C 1.4±0.02
bc 1.5±0.02
b 2.3±0.11
a
ET-1 1 2.3±0.07** 1
b 0.6±0.08
b 0.7±0.14
b 1.3±0.01
a
Values are mean±SE of six rats in each group. *p<0.05, **p<0.01, vs. control in male rats and sham in female rats. Different superscript letters in
female rats show significant differences at p<0.05 by Tukey’ s test.
Table 2. Ratios of the densitometry readings of the RT-PCR amplification of renin, angiotensinogen (Aogen), angiotensin II receptor
subtypes AT1A, AT1B, TGF- 1 and endothelin-1 and GAPDH mRNAs in the right ventricle from the control and monocrotaline (MCT)-
injected male rats, as well as the ovariectomized (Ovx) and the sham-operated female rats
Renin
MCT
GAPDH
Con MCT Sham Ovx Sham Ovx
Fig. 1. Representative photographs of the RT-PCR products for
renin mRNA in the right ventricle of the control and monocrotaline
(MCT)-treated male rats, and the ovariectomized (Ovx) and the
sham-operated female rats. GAPDH mRNA was amplified in par-
allel for the internal control.
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Effect of Estrogen and Enalapril on the Progression
of the Pulmonary Hypertension and RV Hypertrophy:
Histological Evaluation
To substantiate the notion of beneficial effects of estrogen
and inhibition of the renin-angiotensin system on the progres-
sion of the RV hypertrophy, histological changes of the lung
and RV were examined in female rats. RV hypertrophy was
prominent in the Ovx-MCT rats, but not in the sham-MCT
rats and estrogen or enalapril treated Ovx-MCT rats (Table
3). However, lung weight increased in all of the sham-MCT
and the Ovx-MCT rats treated with or without estrogen and
enalapril.
Histological changes of the lung and RV are shown in Fig.
2 and 3, respectively. Compared to the sham-operated female
rats, the lungs of the Ovx rats showed increased alveolar size,
partial atelectasis, thickened interalveolar septa, and slightly
hypertrophied walls of the small arteries. Lungs of the sham-
MCT rats showed prominent atelectasis and hypertrophied walls
of the small arteries, denoting developed pulmonary hyper-
Fig. 2. Light microscopic findings of the lung tissues of the sham-operated (A) or the ovariectomized (Ovx) female rats (B) treated with or
without monocrotaline (MCT). Hematoxylin and eosin stain, scale bar=50  m. The Ovx rats (B) show histological changes such as increased
alveolar size, inflammatory cells (arrows), and mild bronchial obstruction. The sham-MCT rats (C) show hypertrophy of small arteries (white
arrows) and atelectasis (arrow), denoting pulmonary hypertension. The Ovx-MCT (D) rats show severe pathological changes such as dif-
fused atlectasis, fibrosis and hypertrophy of vascular smooth muscle. In contrast, estrogen (E) or enalapril (F) treatment to the Ovx-MCT
rats markedly ameliorate the pathological findings, i.e., patent alveoli, and less prominent hypertrophy of vascular wall.
A
D
B
E
C
F
Ovx-MCT
Sham Sham-MCT Ovx
- Estrogen Enalapril
Weight gain, g 65±5.1 37±2.5 125±9.7 67±3.8 60±4.2 110±10.7
RV/(LV+S) 0.38±0.05 0.42±0.04 0.34±0.05 0.68±0.03 0.34±0.04 0.50±0.08
Lung/BW, ×10
-3 4.4±0.78 7.6±0.58 4.6±0.67 8.3±0.28 7.9±0.60 7.7±0.72
Values are mean±SE of 3 rats in each group.
Table 3. Body weight gain, and heart and lung weights of the sham-operated or the ovarictomized (Ovx) female rats treated with
monocrotaline (MCT) with or without administration of estrogen or enalapriltension. The Ovx-MCT rats, in comparison with the sham-
MCT rats, showed very severe pathological changes such as
obliteration of most alveoli, prominent fibrosis, infiltration of
inflammatory cells, bronchial obstruction, and hypertrophied
vessel walls. The histological findings were similar between
the Ovx-MCT and the male-MCT rats (data not shown). How-
ever, the treatment by using estrogen or enalapril to the Ovx-
MCT rats markedly ameliorated the patholocial changes of
the lungs; patent and almost intact alveoli, and less prominent
hypertrophy of blood vessels.
By the electron microscopy examination of the RV, the sham-
MCT rats did not reveal abnormal findings of the cardiac myo-
cytes, i.e., an intact intercalated disk and striated pattern, but
slightly dialated intramembranous spaces of the diad system
of the T-tuble. In contrast, the Ovx-MCT rats showed very
severe injuries of the hypertrophied RV tissue, i.e., disruption
of the intercalated disk, irregular pattern of cross-striation,
formation of hypercontraction band, fraying of myofibrils, and
aggregation of enlarged mitochondria. Treatment of estrogen
or enalapril to the Ovx-MCT rats remarkably ameliorated the
ultrastructures of the RV myocytes toward the normal.
DISCUSSION
The present study shows that RV hypertrophy was not in-
duced by MCT treatment in female rats, not like in male rats,
as reported previously (4, 14), but was exacerbated after ovariec-
tomy. Although the MCT-treated female rats did not show
RV hypertrophy, they showed histological changes-denoting
moderate pulmonary hypertension. The Ovx-MCT rats showed
remarkable RV hypertrophy with very severe pathological
changes in the lung and RV, and enhanced gene expressions
of the RV RAS. Treatment by using estrogen or enalapril to
the Ovx-MCT rats prevented the RV hypertrophy, and remark-
ably ameliorated the ultrastructural changes in the lung and
RV. These findings from this rat model suggest that estrogen
and the inhibition of the renin-angiotensin system have pro-
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Fig. 3. Electron microscopic findings of the right ventricular wall of the sham-operated (A) or the ovariectomized (Ovx) female rats (B) treat-
ed with or without monocrotaline (MCT). Uranyl acetate and lead citrate stain, scale bar=2  m. The sham-MCT rats (C) show intact interca-
lated disk (line arrow) and striated pattern, but dilated intramembranous spaces of the diad system of T-tubule and sarcoplasmic reticu-
lum (arrows). The Ovx-MCT rats (D) show severe myocardial injuires such as disruption of the intercalated disk (line arrow), formation of a
hypercontraction band (asterik), an irregular pattern of cross-striation, and an aggregation of enlarged mitochondria (M). The right side
shows the disoriented myofilaments of the degenerated cardiac myocyte at the intercalated disk. Estrogen (E) or enalapril (F) treatment
to the Ovx-MCT rats ameliorate the ultrastructure of the RV striated patterns, intercalated disc and mitochondria.
A
D
B
E
C
F
M
M
M
*
*
ID
M
*tective functions against the development of the pulmonary
hypertension and cardiac remodeling.
The protective influences of estrogen on the development
of RV hypertrophy in the present study could potentially result
from both direct and indirect actions on the heart. Estrogen
has been recognized to directly influence cardiac as well as
vascular cells (18). Indeed, functional estrogen  - and  -recep-
tors have been demonstrated in the cardiac myocytes and fi-
broblasts as well as vascular endothelial and smooth muscle
cells (19, 20). Several months after ovariectomy, abnormal
cardiac mass, function, and biochemistry were produced in rats
(21, 22). Estrogen treatment after ovariectomy prevented left
ventricular hypertrophy in rats with spontaneously hyperten-
sive heart failure (21), and improved cardiac performance fol-
lowing global ischemia and reperfusion (23, 24). Estrogen also
attenuated the cardiac hypertrophic response to pressure over-
load by transverse aortic constriction in ovariectomized mice
(25). The antihypertrophic effect was not mediated by the blood
pressure-lowering effect of estrogen. Therefore, these results
support the notion that estrogen has direct protecting effects
on cardiac myocytes and heart.
Considering ultrastructural findings of the lung and RV in
the present study, additional possibility is that the less degree
RV hypertrophy in the sham-MCT female and the E2-treated
Ovx-MCT rats is secondary to lower pulmonary hyperten-
sion. Although pulmonary arterial pressure was not measured
directly in the present study, more severe and prevalent hyper-
trophy of the pulmonary arterial wall of the Ovx-MCT rats
may suggest higher pulmonary hypertension. Considering
the severe atelectasis and lung injury of the Ovx-MCT rats, it
is possible that hypoxia also contributed to the observed arte-
rial remodeling and pulmonary hypertension. Several studies
suggested that ovariectomy augmented chronic hypoxia-
induced pulmonary hypertension, RV hypertrophy and arte-
rial remodeling (26), whereas estrogen attenuated the devel-
opment of pulmonary hypertension induced either by
chronic hypoxia (26) or MCT (27) in rats. In hypoxia-induced
pulmonary hypertension, the protective effects of estrogen
appear to be mediated in part by reduced pulmonary ET-1
expression (28) and associated arterial modeling (26), and
decreased polycythemia (29). Direct beneficial effects of
estrogen on the lung tissue have been reported that ovariec-
tomy decreased gas-exchange surface area and increased
alveolar size, whereas treatment of estrogen prevented the
changes (30). Taken together, estrogen may attenuate the
MCT-induced RV hypertrophy secondary to diminished
pulmonary hypertension. To differentiate relative impor-
tance of direct and indirect cardioprotective roles for estro-
gen in this animal model, the development of RV hypertro-
phy should be compared at similar levels of pulmonary hyper-
tension.
Myocardial hypertrophy is the compensatory response to
a chronic elevation in mechanical workload. It is a complex
process that involves cardiac cell growth and accumulation
of extracellular matrix proteins (6). In cultured cardiac fibro-
blast, estrogen inhibited cell growth, and collagen synthesis
(31). In the pressure-overloaded heart, several vasoactive sub-
stances and growth factors synthesized and released from the
heart may be involved in the process of cardiac remodeling
(6). A critical role of the cardiac RAS, among others, has been
recognized (7). Actually, beneficial effects of an inhibition of
RAS has been shown to decrease ventricular remodeling in-
duced by chronic hypoxia (32, 33) and myocardial infarction
(34, 35).
The present study showed enhanced gene expression of the
renin-angiotensin system components in the hypertrophied
RV of the male MCT rats, as we previously reported (15). Inter-
estingly, although the sham-MCT female rats did not show
RV hypertrophy, they showed a similar degree of increase in
RV renin mRNA level as the male MCT rats. However, the
Ovx-MCT rats showed remarkably greater increase in renin
mRNA level in the hypertrophied RV. This result may suggest
significant interactions between estrogen and cardiac RAS,
and raise a question whether estrogen inhibit cardiac renin
expression. Angiotensinogen mRNA level was also increased
in the hypertrophied RV of the Ovx-MCT rats, but to a less
degree. Although ACE mRNA was not measured in the
present study, we previously reported increased ACE mRNA
in the hypertrophied RV of MCT-male rats (15). Increased
ACE activity and expression in the hypertrophied RV (36), and
plasma levels of renin, ACE and angiotensin II (32) have also
been demonstrated in rats with hypoxic pulmonary hyperten-
sion. In contrast, AT1 receptors do not seem to be changed
in the hypertrophied RV. Adamy et al. (37) also showed no
change in AT1 and AT2 receptors in RV and LV of the MCT-
treated male rats.
Elevated cardiac renin-angiotensin system suggests possi-
ble contribution to the MCT-induced RV hypertrophy. This
hypothesis was supported by the present result that treatment
of enalapril, an ACE inhibitor, prevented RV hypertrophy and
profoundly ameliorated ultrastructural changes of the lung
and RV in the Ovx-MCT rats. Enalapril and estrogen produced
very similar effects. Previous studies also demonstrated the
benefit of ACE inhibitors and AT1 receptor antagonists against
the development of MCT (38)- and hypoxia (32, 33)-induced
pulmonary hypertnesion and RV hypertrophy in male rats.
Inhibitory effects of enalapril against the development of RV
hypertrophy in the present study may also be consequences
of direct cardiac action and secondary to diminished pulmonary
hypertension. In addition, further studies are needed to eval-
uate possible influence of enalapril-induced decrease in systemic
blood pressure on the MCT-induced cardiopulmonary patho-
genesis.
Increased gene expression of TGF- 1 and endothelin-1 in
the hypertrophied RV of the male-MCT and the Ovx-MCT
rats in the present study confirms our previous findings (15).
Both TGF- 1 and endothelin-1 are known to stimulate the
production and accumulation of extracellular matrix proteins
646 B.H. Ahn, H.K. Park, H.G. Cho, et al.in myocardial hypertrophy and fibrosis (39, 40). A blockade
of endothelin-1 prevented MCT-induced pulmonary hyper-
tension and RV hypertrophy (41, 42) suggesting that endoge-
nous endothelin-1 contributes to the progression of cardiopul-
monary alterations. On the other hand, TGF- 1mRNA expres-
sion was slightly but significantly increased even in the unhy-
pertrophied RV of the Ovx control and the sham-MCT female
rats, but increased further in the hypertrophied RV of the Ovx-
MCT rats. The result from this rat model may suggest a sup-
pressive effect of estrogen on cardiac TGF- 1 expression and
cardiac remodeling.
In summary, our results demonstrate gender differences and
beneficial effects of the ovarian function and the inhibition
of the renin-angiotensin system on the development of MCT-
induced pulmonary hypertension and RV hypertrophy. En-
hanced gene expression of the cardiac renin-angiotensin sys-
tem, TGF- 1 and endothelin-1 in the hypertrophied RV of the
Ovx-MCT rats may suggest the interaction of these cardiac
vasoactive substances with estrogen. However, further inves-
tigations are required to understand underlying mechanisms
of the interactions in the pathogenesis of heart disease.
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